Post by account_disabled on Feb 20, 2024 3:22:08 GMT -5
The vaccine jointly developed by the University of Oxford and AstraZeneca was the first to set a date for the launch of its prototype . “We will be ready to deliver from October, if all goes well,” Adrian Hill, one of the scientists carrying out the research , ventured to say in June. The key is in that tagline – “if everything goes well” – and that is that, almost four months later, and after several setbacks, optimism has been reduced to such an extent that the United Kingdom has admitted that the possibility of this antidote be ready before Christmas is “minimal”. This was stated by Kate Bingham, chair of the UK vaccine working group, in an interview on Sky News, in which she indicated that, although she hopes that clinical trials will show signs of success by the end of the year , she could not give guarantee .
I think there is a small chance that we can have the Oxford vaccine before Christmas ," explained the expert, always with an optimistic tone, but insisted that many uncertainties still persist about how much protection they provide and for how long , what more will be needed. candidates. “We're not done yet,” she asserted. Read more: Antibody-dependent Middle East Phone Number List infection: the worst nightmare of scientists investigating the coronavirus and which could endanger vaccines Bingham's statements come a month after Boris Johnson's government's chief scientific adviser, Patrick Vallance, suggested that the most vulnerable people could start receiving the vaccine before the end of 2020 , with the intention of vaccinating the rest of the population.
the population for next year. Spain expected three million doses by December The Minister of Health, Salvador Illa, announced last month that Spain could receive three million doses of the Oxford antidote in December, provided that it had passed all clinical tests by then . The European Union committed to purchasing 30 million doses of this vaccine, of which an initial 10% would go to Spain. But since then the investigation has suffered several delays . At the beginning of September, the clinical trials were halted due to the adverse and "unexplained" reaction of one of the participants. However, AstraZeneca explained that this was a "routine" action in this type of research.